ClinicalTrials.Veeva

Menu

Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

C

Canadian Paediatric Society

Status

Unknown

Conditions

Invasive Meningococcal Disease

Treatments

Other: surveillance

Study type

Observational

Funder types

Other
Industry

Identifiers

Details and patient eligibility

About

Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.

Full description

The objectives are 3-fold, including:

  1. description of affected children and adults and the nature and outcome of the infection episodes
  2. incidence rate determination in defined populations, by age, serogroup and study year
  3. detailed study of the organisms recovered from cases

Enrollment

400 estimated patients

Sex

All

Ages

1+ minute old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:Neisseria meningitidis isolated or detected by PCR from a normally sterile body site or fluid, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy -

Exclusion Criteria:patients diagnosed based only on

  1. clinical signs, gram stain, or antigen test
  2. meningococci isolated only from respiratory tract, including conjunctiva, sinuses, middle ear/mastoid, throat, peritonsillar abscess, cervical lymph node, tracheal aspirate, bronchial lavage etc -

Trial design

400 participants in 1 patient group

Persons of all ages
Description:
Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy
Treatment:
Other: surveillance

Trial documents
2

Trial contacts and locations

13

Loading...

Central trial contact

Marie Adele Davis; Melanie Laffin Thibodeau

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems